Compare Unichem Lab with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB PIRAMAL ENTERPRISES UNICHEM LAB/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 60.9 17.6 346.2% View Chart
P/BV x 0.7 1.1 58.6% View Chart
Dividend Yield % 2.1 1.6 133.4%  

Financials

 UNICHEM LAB   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    UNICHEM LAB
Mar-19
PIRAMAL ENTERPRISES
Mar-19
UNICHEM LAB/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2923,303 8.8%   
Low Rs1821,797 10.1%   
Sales per share (Unadj.) Rs167.7716.5 23.4%  
Earnings per share (Unadj.) Rs-3.679.7 -4.6%  
Cash flow per share (Unadj.) Rs5.9107.9 5.5%  
Dividends per share (Unadj.) Rs4.0028.00 14.3%  
Dividend yield (eoy) %1.71.1 153.7%  
Book value per share (Unadj.) Rs372.31,477.5 25.2%  
Shares outstanding (eoy) m70.38184.45 38.2%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x1.43.6 39.7%   
Avg P/E ratio x-65.332.0 -204.1%  
P/CF ratio (eoy) x39.923.6 168.8%  
Price / Book Value ratio x0.61.7 36.9%  
Dividend payout %-110.235.1 -313.6%   
Avg Mkt Cap Rs m16,680470,292 3.5%   
No. of employees `0002.67.8 33.3%   
Total wages/salary Rs m2,39322,504 10.6%   
Avg. sales/employee Rs Th4,535.216,899.4 26.8%   
Avg. wages/employee Rs Th919.82,877.7 32.0%   
Avg. net profit/employee Rs Th-98.21,879.9 -5.2%   
INCOME DATA
Net Sales Rs m11,801132,153 8.9%  
Other income Rs m9843,128 31.5%   
Total revenues Rs m12,785135,281 9.5%   
Gross profit Rs m-83566,290 -1.3%  
Depreciation Rs m6745,202 13.0%   
Interest Rs m7544,097 0.2%   
Profit before tax Rs m-60020,119 -3.0%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-3438,611 -4.0%   
Profit after tax Rs m-25614,701 -1.7%  
Gross profit margin %-7.150.2 -14.1%  
Effective tax rate %57.342.8 133.8%   
Net profit margin %-2.211.1 -19.5%  
BALANCE SHEET DATA
Current assets Rs m20,384122,742 16.6%   
Current liabilities Rs m5,029310,810 1.6%   
Net working cap to sales %130.1-142.3 -91.4%  
Current ratio x4.10.4 1,026.4%  
Inventory Days Days10523 454.1%  
Debtors Days Days13539 347.3%  
Net fixed assets Rs m9,023116,904 7.7%   
Share capital Rs m141369 38.2%   
"Free" reserves Rs m26,058272,161 9.6%   
Net worth Rs m26,199272,530 9.6%   
Long term debt Rs m0270,196 0.0%   
Total assets Rs m31,496856,261 3.7%  
Interest coverage x-7.01.5 -479.0%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.40.2 242.8%   
Return on assets %-0.66.9 -8.3%  
Return on equity %-1.05.4 -18.1%  
Return on capital %-2.012.4 -16.1%  
Exports to sales %69.40-   
Imports to sales %00-   
Exports (fob) Rs m8,188NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m8,18815,200 53.9%   
Fx outflow Rs m5964,889 12.2%   
Net fx Rs m7,59210,312 73.6%   
CASH FLOW
From Operations Rs m-3,278-115,975 2.8%  
From Investments Rs m-2,860-8,265 34.6%  
From Financial Activity Rs m-24107,525 -0.0%  
Net Cashflow Rs m-4,690-16,650 28.2%  

Share Holding

Indian Promoters % 50.1 52.9 94.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 4.0 377.5%  
FIIs % 3.0 26.6 11.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 16.5 192.1%  
Shareholders   20,176 93,274 21.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare UNICHEM LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 19, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - SANOFI INDIA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS